In a world where the traditional way of conducting business has been disrupted for most of the year, companies for the most part appear to have adapted well to the prevailing environment. BioWorld conducted a short poll to determine readers’ own experiences during these challenging times and how they believed this new normal might reshape their approach to doing business going forward.
There has been a recent renaissance in the interest in radiopharmaceuticals used for diagnostic and therapeutic applications, as well as their combined use (theranostics). A recent Canadian partnership between Admare Bioinnovations and the Centre for Probe Development and Commercialization (CPDC) aims to take advantage of the country’s expertise in the field and leverage promising radiopharmaceutical innovations into potential commercial opportunities.
Although the global impact of a novel virus like SARS-CoV-2 has so far reached devastating proportions, it has spurred science at an unprecedented rate with potential vaccines developed under a year now nearing U.S. authorization. But while some may say the end to this pandemic is in sight, an actual date is blurry at best, as manufacturing and supply capabilities muddy the outlook.
The Society for Immunotherapy of Cancer meeting, which concludes on Nov. 14, features a wide range of sessions that delve into the most recent advances in tumor immunology and cancer immunotherapy, providing an excellent opportunity for investors and analysts alike to stay up to date on new therapeutics to improve cancer treatments. Overall, data presented at the meeting appears to have been well received, a factor that has helped push up the value of the price weighted BioWorld Cancer index this month.
According to an analysis conducted by BioWorld of the third-quarter 2020 financial reports filed by public biopharmaceutical companies with market caps greater than $1 billion, and excluding big pharma companies, the amount that was invested in research and development (R&D) during the nine-month period increased by almost 21% compared to the same period last year. The spending was bolstered by companies turning their attention to focus their research on therapies and vaccines to tackle COVID-19.
RSS
